Northside Capital Management LLC Has $12.59 Million Stock Holdings in Medtronic PLC $MDT

Northside Capital Management LLC boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 18.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,012 shares of the medical technology company’s stock after acquiring an additional 20,685 shares during the quarter. Northside Capital Management LLC’s holdings in Medtronic were worth $12,585,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of MDT. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter worth $27,000. Board of the Pension Protection Fund acquired a new stake in Medtronic in the fourth quarter valued at $29,000. GoalVest Advisory LLC acquired a new stake in Medtronic in the fourth quarter valued at $29,000. Valley Wealth Managers Inc. bought a new position in Medtronic during the 3rd quarter worth $29,000. Finally, Delos Wealth Advisors LLC bought a new position in Medtronic during the 2nd quarter worth $27,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

MDT stock opened at $86.29 on Friday. The firm has a market cap of $110.78 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $96.82 and a 200-day moving average price of $96.69. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 EPS. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio is presently 79.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Barclays reiterated an “overweight” rating and issued a $118.00 price target on shares of Medtronic in a research report on Wednesday, February 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $120.00 price objective on shares of Medtronic in a research note on Tuesday, March 10th. Robert W. Baird reduced their target price on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Finally, Leerink Partners restated an “outperform” rating and set a $119.00 price target on shares of Medtronic in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by company insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).